Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.15
AMRI's Cash to Debt is ranked lower than
53% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. AMRI: 0.15 )
AMRI' s 10-Year Cash to Debt Range
Min: 0.15   Max: No Debt
Current: 0.15

Equity to Asset 0.46
AMRI's Equity to Asset is ranked higher than
60% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. AMRI: 0.46 )
AMRI' s 10-Year Equity to Asset Range
Min: 0.46   Max: 0.96
Current: 0.46

0.46
0.96
Interest Coverage 16.08
AMRI's Interest Coverage is ranked higher than
52% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMRI: 16.08 )
AMRI' s 10-Year Interest Coverage Range
Min: 1.52   Max: 1157.93
Current: 16.08

1.52
1157.93
F-Score: 4
Z-Score: 2.10
M-Score: 1.24
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 3.80
AMRI's Operating margin (%) is ranked higher than
85% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. AMRI: 3.80 )
AMRI' s 10-Year Operating margin (%) Range
Min: -36.43   Max: 138.11
Current: 3.8

-36.43
138.11
Net-margin (%) 1.46
AMRI's Net-margin (%) is ranked higher than
83% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. AMRI: 1.46 )
AMRI' s 10-Year Net-margin (%) Range
Min: -31.74   Max: 85.42
Current: 1.46

-31.74
85.42
ROE (%) 1.55
AMRI's ROE (%) is ranked higher than
86% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. AMRI: 1.55 )
AMRI' s 10-Year ROE (%) Range
Min: -22.52   Max: 29.88
Current: 1.55

-22.52
29.88
ROA (%) 0.83
AMRI's ROA (%) is ranked higher than
86% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. AMRI: 0.83 )
AMRI' s 10-Year ROA (%) Range
Min: -17.99   Max: 23.52
Current: 0.83

-17.99
23.52
ROC (Joel Greenblatt) (%) 4.70
AMRI's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. AMRI: 4.70 )
AMRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.34   Max: 157.7
Current: 4.7

-35.34
157.7
Revenue Growth (%) 7.30
AMRI's Revenue Growth (%) is ranked higher than
83% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. AMRI: 7.30 )
AMRI' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 72.8
Current: 7.3

-1.5
72.8
» AMRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

AMRI Guru Trades in Q4 2013

Chuck Royce 1,412,568 sh (+42.01%)
Joel Greenblatt 229,437 sh (+0.54%)
Murray Stahl 56,000 sh (unchged)
Jim Simons 512,600 sh (-14.13%)
» More
Q1 2014

AMRI Guru Trades in Q1 2014

Steven Cohen 25,400 sh (New)
George Soros 48,700 sh (New)
Jim Simons 696,690 sh (+35.91%)
Murray Stahl 56,000 sh (unchged)
Chuck Royce 1,344,610 sh (-4.81%)
Joel Greenblatt 197,771 sh (-13.8%)
» More
Q2 2014

AMRI Guru Trades in Q2 2014

Murray Stahl 56,000 sh (unchged)
George Soros Sold Out
Chuck Royce 1,315,610 sh (-2.16%)
Jim Simons 579,842 sh (-16.77%)
Joel Greenblatt 102,934 sh (-47.95%)
» More
Q3 2014

AMRI Guru Trades in Q3 2014

Paul Tudor Jones 16,255 sh (New)
Murray Stahl 56,000 sh (unchged)
Joel Greenblatt Sold Out
Chuck Royce 1,142,670 sh (-13.15%)
Jim Simons 209,242 sh (-63.91%)
» More
» Details

Insider Trades

Latest Guru Trades with AMRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Sold Out 0.03%$18.7 - $22.89 $ 16.27-20%0
Joel Greenblatt 2014-06-30 Reduce -47.95%0.03%$14.63 - $19.89 $ 16.27-4%102934
George Soros 2014-06-30 Sold Out 0.01%$14.63 - $19.89 $ 16.27-4%0
George Soros 2014-03-31 New Buy0.01%$10.08 - $19.91 $ 16.2720%48700
Joel Greenblatt 2013-09-30 New Buy0.1%$10.81 - $13.72 $ 16.2732%228216
John Rogers 2013-03-31 Sold Out 0.04%$5.28 - $10.84 $ 16.27115%0
John Rogers 2012-12-31 Reduce -27.34%0.01%$3.45 - $5.5 $ 16.27283%372844
John Rogers 2012-06-30 New Buy0.03%$2.32 - $3.22 $ 16.27479%473769
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 171.30
AMRI's P/E(ttm) is ranked higher than
88% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRI: 171.30 )
AMRI' s 10-Year P/E(ttm) Range
Min: 12.98   Max: 1328
Current: 171.3

12.98
1328
P/B 2.15
AMRI's P/B is ranked higher than
90% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. AMRI: 2.15 )
AMRI' s 10-Year P/B Range
Min: 0.28   Max: 3.05
Current: 2.15

0.28
3.05
P/S 1.99
AMRI's P/S is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. AMRI: 1.99 )
AMRI' s 10-Year P/S Range
Min: 0.31   Max: 2.93
Current: 1.99

0.31
2.93
EV-to-EBIT 65.05
AMRI's EV-to-EBIT is ranked higher than
89% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRI: 65.05 )
AMRI' s 10-Year EV-to-EBIT Range
Min: -448.8   Max: 333.6
Current: 65.05

-448.8
333.6
Current Ratio 2.91
AMRI's Current Ratio is ranked higher than
64% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. AMRI: 2.91 )
AMRI' s 10-Year Current Ratio Range
Min: 2.45   Max: 17.83
Current: 2.91

2.45
17.83
Quick Ratio 1.88
AMRI's Quick Ratio is ranked higher than
61% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. AMRI: 1.88 )
AMRI' s 10-Year Quick Ratio Range
Min: 1.84   Max: 17.25
Current: 1.88

1.84
17.25

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 3.58
AMRI's Price/Tangible Book is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. AMRI: 3.58 )
AMRI' s 10-Year Price/Tangible Book Range
Min: 0.39   Max: 16.72
Current: 3.58

0.39
16.72
Price/DCF (Projected) 2.43
AMRI's Price/DCF (Projected) is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRI: 2.43 )
AMRI' s 10-Year Price/DCF (Projected) Range
Min: 0.4   Max: 3.3
Current: 2.43

0.4
3.3
Price/Median PS Value 1.19
AMRI's Price/Median PS Value is ranked higher than
84% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. AMRI: 1.19 )
AMRI' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 24.95
Current: 1.19

0.22
24.95
Price/Graham Number 4.73
AMRI's Price/Graham Number is ranked higher than
91% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMRI: 4.73 )
AMRI' s 10-Year Price/Graham Number Range
Min: 0.84   Max: 8.11
Current: 4.73

0.84
8.11
Earnings Yield (Greenblatt) 1.50
AMRI's Earnings Yield (Greenblatt) is ranked higher than
88% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. AMRI: 1.50 )
AMRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 15.1
Current: 1.5

0.3
15.1
Forward Rate of Return (Yacktman) 18.08
AMRI's Forward Rate of Return (Yacktman) is ranked higher than
87% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -6.41 vs. AMRI: 18.08 )
AMRI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -17.9   Max: 24.2
Current: 18.08

-17.9
24.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AYM.Germany
Albany Molecular Research Inc is a Delaware corporation incorporated on June 20, 1991. It is a contract research and manufacturing organization providing customers integrated drug discovery, development and manufacturing services. The Company provides services and technologies that support the discovery and development of pharmaceutical products and the manufacturing of Active Pharmaceutical Ingredients (API) and drug product for existing and experimental new drugs, as well as research, development and manufacturing for the agrochemical and other industries. With locations in the United States, Europe, and Asia, it maintains geographic proximity and flexible cost models. The Company has organized its activities into two distinct segments: Large Scale Manufacturing (LSM) and Discovery, Drug Development and Small-Scale Manufacturing (DDS). Its LSM activities include pilot- to commercial-scale production of active pharmaceutical ingredients and intermediates, sterile syringe and vial filling, and high potency and controlled substance manufacturing. Its remaining activities, including drug lead discovery, in vitro biology and DMPK, lead optimization, drug development, and small-scale commercial manufacturing, represent its DDS business segment. Its Drug Discovery Services includes assay development and design, screening, natural product services, custom synthesis and library synthesis, medicinal chemistry, bioanalytical services, among others. Its customers include pharmaceutical companies and biotechnology companies, as well as government research entities and non-profit organizations, which are a growing segment of its customer base. It also sells to a more limited extent, to companies who are in the businesses of agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics. The Company competes with contract research companies, contract drug manufacturing companies, research and academic institutions and with the internal research departments of biotechnology companies. The manufacture, transportation and storage of its products are subject to certain international, Federal, state and local laws and regulations.
» More Articles for AMRI

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: TSON, PRTS, FXCM, AMRI, MN Dec 05 2011 
View on AMRI Jun 27 2010 
AMRI Announces Second Quarter 2009 Results Aug 04 2009 
AMRI Announces Fourth Quarter 2008 Results Feb 09 2009 
AMRI Names Senior Director, Analytical and Quality Services Jan 12 2009 

More From Other Websites
SECURITIES ALERT: Rosen Law Firm Reminds Albany Molecular Research, Inc. Investors of Important... Nov 28 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000... Nov 26 2014
INVESTOR ALERT: Class Action Lawsuit Against Albany Molecular Research Inc. Announced by Law Offices... Nov 21 2014
ALBANY MOLECULAR RESEARCH INC Financials Nov 21 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Nov 19 2014
INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000... Nov 19 2014
AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational Nov 19 2014
INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the... Nov 19 2014
Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Albany Molecular Research Inc. Nov 14 2014
Harwood Feffer LLP Announces Investigation of Albany Molecular Research Inc. Nov 14 2014
Class Action Lawsuit on Behalf of Albany Molecular Research Inc. Investors Announced by Kirby... Nov 14 2014
Robbins Arroyo LLP: Albany Molecular Research, Inc. (AMRI) Misled Shareholders According to a... Nov 14 2014
Albany Molecular Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate... Nov 14 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... Nov 13 2014
AMRI SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Albany... Nov 13 2014
INVESTOR ALERT: Class Action Lawsuit Against Albany Molecular Research Inc. Announced By Glancy... Nov 13 2014
AMRI CEO to Present at the 2014 Credit Suisse Healthcare Conference Nov 13 2014
AMRI Announces Third Quarter 2014 Results Nov 13 2014
AMRI to Announce Third Quarter Results on November 5, 2014 Nov 13 2014
10-Q for Albany Molecular Research, Inc. Nov 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK